Delivery Order SPE2DB20D3101-SPE2DB25FRAE9

Award Date 1/28/25
Potential Completion Date 1/29/25
Potential Value $4.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order valued at $2,891.52 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 40 units of Amox-Clav ER 1,000-62.5 mg tablets, a prescription medication. The contract has a firm fixed price and an ultimate completion date of January 31, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,184.03 firm fixed-price delivery order is for the supply of AMOX-CLAV 875-125 MG TABLET 20S, a generic antibiotic medication. The contract has an ultimate completion date of November 14, 2024 and was awarded on November 13, 2024. This award is associated with a larger $999,999,999 Indefinite Delivery Contract...
This federal contract award is for a Delivery Order (DO) valued at $5,976.76, issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of AMOX-CLAV 400-57 MG TAB CHEW 20S, a medical product. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,668.36 firm fixed-price contract is for the delivery of 4567056020 AMOX-CLAV 875-125 MG TABLET 20S, a pharmaceutical product. The contract has an ultimate completion date of January 28, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $1,523.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of AMOX-CLAV 875-125 MG TABLET UD 100S, a medical product used for various healthcare needs. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of January 3, 2025. It is not designated as a set-aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,543.50 firm fixed-price delivery order is for the supply of 4565751440 AMOX-CLAV 500-125 MG TABLET 20S. The contract has a completion date of September 11, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,668.84 delivery order contract is for the procurement of AMOX-CLAV 875-125 MG TABLET 20S, a pharmaceutical product. The contract has a firm fixed price pricing type and a completion date of May 12, 2023. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,060.03 firm fixed-price delivery order is for AMOX-CLAV 250-125 MG TABLET 30S, a generic pharmaceutical product. The award is not designated under any set-aside program. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $1,265.87 delivery order is for the supply of Amox-Clav 875-125 mg tablets, a prescription medication. The contract has a firm-fixed price and an ultimate completion date of December 15, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,550.61, is a Firm Fixed Price Delivery Order for the supply of pharmaceutical products, specifically Amoxicillin-Clavulanate 1,000-62.5 mg tablets. The award has an ultimate completion date of January 22, 2025. This contract is not a set-aside and represents open competition. Amerisourcebergen...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB25FRAE9
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,307.04 fixed-price delivery order is for the supply of AMOX-CLAV ER 1,000-62.5 MG TAB UU 28S, with a completion date of January 29, 2025. The contract is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award did not have a set-aside designation, indicating open competition.

Generated 4/29/25, 9:46 AM